DJO Global is putting the “therapy” in retail therapy: The surgical device maker has now made five acquisitions since last November, with all but one in the reconstructive surgery space.
Medtronic scored FDA approval for its latest spinal cord stimulation implant for chronic pain, with a non-rechargeable device promising nearly double the battery life of previous hardware.
Acumen Pharmaceuticals is filing for a $100 million initial public offering hot on the heels of the FDA’s conditional approval of Biogen’s controversial Alzheimer’s disease drug Aduhelm (aducanumab).
With a new CEO in place and its revenues on the rebound after a tumultuous 2020, Inogen is looking to make its product line of at-home and portable oxygen concentrators bigger and better than ever.
Though osteoarthritis of the knee is estimated to affect at least 14 million people in the U.S. alone, treatments for the degenerative joint disease remain woefully limited.
A class of antidepressants known as monoamine oxidase inhibitors (MAOIs) first hit the market in the 1950s and has since been eclipsed by drugs that are less likely to cause unwanted side effects. Now, scientists at the University of California, Los Angeles (UCLA) have evidence that these drugs may be able to be repurposed in the treatment of cancer.
With the goal of making data a facet of every healthcare decision—and spinning that information back into life science research—Datavant and the medical records platform developer Ciox Health, plus their VC backers, have agreed to lay out $7 billion to combine their enterprises.
Another member of the FDA’s advisory committee on nervous system drugs has quit over the approval of Biogen’s Alzheimer’s disease product Aduhelm, Reuters reports. Mayo Clinic neurologist David Knopman, M.D., is the latest expert to leave the committee because of the FDA approval.
For patients undergoing deep brain stimulation, the work of programming the device and adjusting its treatment can be a laborious trial-and-error process, with regular neurologist appointments spanning years to get the settings just right.
If a Big Pharma’s entire R&D enterprise can be likened to a cruise ship, an unwieldy carrier of thousands of people, you might not see it turn fast enough to meet new hazards on the horizon—but give it an accurate map and enough warning, and it will sail right through.